Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3837-3842

  Notarnicola, Maria ^a   Messa, Caterina ^a   Pricci, Maria ^a   Guerra, Vito ^a   Altomare, Donato Francesco ^b   Montemurro, Severino ^c   Caruso, Maria Gabriella ^a,d  

^a Natl Institute of Digestive Disease   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Apoptosis; Cell proliferation; Colon cancer; HMGCoA reductase

Indexed keywords

DNA FRAGMENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN CACO 2; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; UPREGULATION; COLON TUMOR; ENZYMOLOGY; METABOLISM; PATHOLOGY;

AGED; CACO-2 CELLS; COLONIC NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RECEPTORS, LDL; SIMVASTATIN; UP-REGULATION;

EID: 14944372177     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Tavangar K and Kraemer FB: The regulation of hydroxymethylglutaryl-CoA reductase in cultured cells. Biochimica et Biophysica Acta 970: 251-261, 1988.
2. Edwards PA and Ericsson J: Sterols and isoprenoids: signalling molecules derived from the cholesterol biosynthetic pathway. Ann Rev Biochem 68: 157-185, 1999.
3. Rudling MJ, Angelin B, Peterson CO and Collins VP: Low density lipoprotein receptor activity in human intracranial tumors and its relation to cholesterol requirement. Cancer Res 50: 483-487, 1990.
4. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25: 1462-1468, 1984.
5. Holstein SA, Wohlford-Lenane CL and Hohl RJ: Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41: 13698-13704, 2002.
6. Maltese WA: 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 33: 1294-1299, 1983.
7. Chen HW, Kandutsch AA and Heineger HJ: The role of cholesterol in malignancy. Prog Exp Tumor Res 22: 275-316, 1978.
8. Newmark HL: Squalene, olive oil, and cancer risk. Review and hypothesis. Ann NY Acad Sci 889: 193-203, 1999.
9. Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y and Tarni S: Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 50: 3270-3273, 1990.
10. O'Donnell VJ, Ottolenghi P, Malkin A, Deusted OF and Herad RD: The biosynthetic from acetate-1-C14 of fatty acids and cholesterol in formed blood elements. Can J Biochem 36: 1125-1136, 1958.
11. Harwood HJ Jr, Alvarez IM, Noyes WD and Stapcpcole PW: In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl Coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukaemia and lymphoma. J Lipid Res 32: 1237-1252, 1991.
12. Maltese WA: 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 33: 1294-1299, 1983.
13. Caruso MG, Notarnicola M, Cavallini A and Di Leo A: 3-Hydroxy-3- methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol 37: 1-5, 2002.
14. Caruso MG, Notarnicola M, Santillo M, Cavallini A and Di Leo A: Enhanced 3-HMGCoA reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res 19: 451-454, 1999.
15. Caruso MG, Osella AR, Notarnicola M, Berloco P, Leo S, Bonfiglio C and Di Leo A: Prognostic value of low density lipoprotein receptor expression in colorectal carcinoma. Oncol Rep 5: 927-930, 1998.
16. Bennis F, Favre G, Le Gallard F and Soula G: Importance of mevalonate-derived products in the control of HMGCoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55: 640-645, 1993.
17. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P and Fumagalli R: Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergetic effect with N,N′-bis (2-cloroethyl)-N-nitrosourea and interferon β on human glioma cells. Cancer Res 52: 4348-4355, 1992.
18. Caruso MG, Notarnicola M, Cavallini A, Guerra V, Misciagna G and Di Leo A: Demonstartion of low density lipoprotein receptor in human colonic carcinoma and surrounding mucosa by immunoenzymatic assay. Ital J Gastroenterol 25: 361-367, 1993.
19. Roehm NW, Rodgers GH, Hatfield SM and Glasebrook AL: An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt MTT. J Immunol Methods 142: 257-265, 1991.
20. Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RAEM, Moriya Y, van de Velde CJH and van Krieken JHJM: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195: 171-178, 2001.
21. Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer 101: 403-408, 2002.
22. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel J-C and Belin B: Dukes B colorectal cancer. Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44: 364-373, 2001.
23. Messa C, Russo F, Caruso MG and Di Leo A: EGF, TGF-a and EGF-R in human colorectal adenocarcinoma. Acta Oncologica 37: 285-289, 1998.
24. Roncucci L, Scalmati A and Ponz de Leon M: Pattern of cell kinetics in colorectal mucosa of patients with different types of adenomatous polyps of the large bowel. Cancer 68: 873-878, 1991.
25. Reichmann A and Levin B: Marker chromosomes in direct preparation of human large bowel tumors. Cancer Genet Cytogenet 16: 229-233, 1985.
26. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ: Isoprenoid addition to ras proteins is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992.
27. Caruso MG, Notarnicola M, Bifulco M, Laezza C, Guerra V, Altomare DF, Memeo V, Lorusso D, Demma I and Di Leo A: Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation. Scand J Gastroenterol 38(1): 80-85, 2003.
28. Muller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H and Koch OM: Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncology 12: 717-723, 1998.
29. DeClue JE, Vass WC, Papageorge AG, Lowy DR and Willumssen BM: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51: 712-717, 1991.
30. Rubins JB, Greatens TG, Kratzke RA, Tan AT, Polunovsky VA and Bitterman P: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157: 1616-1622, 1998.